Literature DB >> 31820453

How do I … implement diagnostic management teams in transfusion medicine?

Jenna Wade1, Christina L Dean1, Scott M Krummey1, John D Roback1, Harold C Sullivan1.   

Abstract

Diagnostic management teams (DMTs) were conceptualized approximately twenty years ago in response to increasing subspecialization in medicine. DMTs are a collaboration between diagnostic experts and clinicians that aim to improve accurate and timely diagnosis and treatment of disease. Diagnostic experts provide their expertise in the increasingly complex realm of laboratory testing and interpretation of those test results to guide appropriate test utilization for individual patients. Not only can this approach improve patient care and safety, but DMTs also decrease healthcare costs by reducing unnecessary testing and potential diagnostic errors. Following the DMT construct and principles along with the 2015 National Academy of Medicine recommendations, our transfusion medicine (TM) service streamlined the workup and management of platelet refractory (PR) patients by developing and implementing a formal PR laboratory consult. The goals of this DMT and consult are to improve diagnostic management of PR patients and to decrease delays in providing these patients with appropriate and compatible platelet units. A comprehensive interpretation of test results is directly uploaded to the patient's electronic medical record (EMR), which is associated with a CPT code allowing for compensation for the PR evaluation. Herein we describe the development of and experience with the DMT since its implementation.
© 2019 AABB.

Entities:  

Mesh:

Year:  2019        PMID: 31820453      PMCID: PMC7341022          DOI: 10.1111/trf.15618

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  23 in total

1.  Frequency and causes of refractoriness in multiply transfused patients.

Authors:  T J Legler; I Fischer; J Dittmann; G Simson; R Lynen; A Humpe; J Riggert; E Schleyer; W Kern; W Hiddemann; M Köhler
Journal:  Ann Hematol       Date:  1997-04       Impact factor: 3.673

2.  Crossmatch-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets.

Authors:  A B Gelb; A D Leavitt
Journal:  Transfusion       Date:  1997-06       Impact factor: 3.157

3.  The new diagnostic team.

Authors:  Mark L Graber; Diana Rusz; Melissa L Jones; Diana Farm-Franks; Barbara Jones; Jeannine Cyr Gluck; Dana B Thomas; Kelly T Gleason; Kathy Welte; Jennifer Abfalter; Marie Dotseth; Kathleen Westerhaus; Josanne Smathers; Ginny Adams; Michael Laposata; Tina Nabatchi; Margaret Compton; Quentin Eichbaum
Journal:  Diagnosis (Berl)       Date:  2017-11-27

4.  What's New in Laboratory Test Utilization Management?

Authors:  Geoffrey S Baird; Brian R Jackson; Jane Dickerson; Ken Sikaris; Bernard Croal; Michael Laposata
Journal:  Clin Chem       Date:  2018-04-09       Impact factor: 8.327

5.  Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity.

Authors:  L D Petz; G Garratty; L Calhoun; B D Clark; P I Terasaki; C Gresens; J A Gornbein; E M Landaw; R Smith; J M Cecka
Journal:  Transfusion       Date:  2000-12       Impact factor: 3.157

Review 6.  Platelet refractoriness--practical approaches and ongoing dilemmas in patient management.

Authors:  Simon J Stanworth; Cristina Navarrete; Lise Estcourt; Judith Marsh
Journal:  Br J Haematol       Date:  2015-07-20       Impact factor: 6.998

7.  Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients.

Authors:  Sherrill J Slichter; Kathryn Davis; Helen Enright; Hayden Braine; Terry Gernsheimer; Kuo-Jang Kao; Thomas Kickler; Edward Lee; Janice McFarland; Jeffrey McCullough; Glenn Rodey; Charles A Schiffer; Robert Woodson
Journal:  Blood       Date:  2005-02-03       Impact factor: 22.113

8.  Relative importance of immune and non-immune causes of platelet refractoriness.

Authors:  H A Doughty; M F Murphy; P Metcalfe; A Z Rohatiner; T A Lister; A H Waters
Journal:  Vox Sang       Date:  1994       Impact factor: 2.144

9.  HLA-Mediated Platelet Refractoriness.

Authors:  Amy E Schmidt; Majed A Refaai; Myra Coppage
Journal:  Am J Clin Pathol       Date:  2019-03-01       Impact factor: 2.493

10.  How do I … manage the platelet transfusion-refractory patient?

Authors:  Justin E Juskewitch; Andrew P Norgan; Steven R De Goey; Patti M Duellman; Laurie L Wakefield; Manish J Gandhi; James R Stubbs; Justin D Kreuter
Journal:  Transfusion       Date:  2017-09-28       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.